SPP1 and neoplasm: Accordingly, our data supports several alternative approaches for inhibiting immune-modulatory pSTAT3+ myMAFs, including progranulin, LIF, and osteopontin, which warrants further investigation for combination with ICT to further harness and unleash the anti-tumour immune response.